Diaz-Riascos Zamira Vanessa, Ginesta Mireia M, Fabregat Joan, Serrano Teresa, Busquets Juli, Buscail Louis, Cordelier Pierre, Capellá Gabriel
Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBERONC, Centro de Investigación Biomédica en Red en Cáncer, Madrid, Spain.
Mol Ther Nucleic Acids. 2019 Sep 6;17:491-503. doi: 10.1016/j.omtn.2019.06.015. Epub 2019 Jun 29.
MicroRNAs from the miR-200 family are commonly associated with the inhibition of the metastatic potential of cancer cells, following inhibition of ZEB transcription factors expression and epithelial-to-mesenchymal transition. However, previous studies performed in pancreatic adenocarcinoma revealed a more complex picture challenging this canonical model. To gain better insights into the role of miR-200 family members in this disease, we analyzed the expression of miR-200a, miR-200b, miR-200c, miR-141, miR-429, and miR-205, and ZEB1, ZEB2, and CDH1 in pancreatic tumors and matching normal adjacent parenchyma and patient-derived xenografts. We found that miR-200a, miR-429, and miR-205 are frequently overexpressed in pancreatic tumors, whereas CDH1 is downregulated, and ZEB1 and ZEB2 levels remain unchanged. Furthermore, we measured a positive correlation between miR-200 family members and CDH1 expression, and a negative correlation between ZEB1 and miR-200c, miR-141, and miR-205 expression, respectively. Interestingly, we identified significant changes in expression of epithelial-to-mesenchymal transition regulators and miR-200 members in patient-derived xenografts. Lastly, functional studies revealed that miR-141 and miR-429 inhibit the tumorigenic potential of pancreatic cancer cells. Taken together, this comprehensive analysis strongly suggests that miRNAs from the miR-200 family, and in particular miR-429, may act as a tumor suppressor gene in pancreatic cancer.
miR-200家族的微小RNA通常与抑制癌细胞的转移潜能相关,这是在抑制ZEB转录因子表达和上皮-间质转化之后发生的。然而,先前在胰腺腺癌中进行的研究揭示了一幅更为复杂的图景,对这一经典模型提出了挑战。为了更好地了解miR-200家族成员在这种疾病中的作用,我们分析了miR-200a、miR-200b、miR-200c、miR-141、miR-429和miR-205,以及ZEB1、ZEB2和CDH1在胰腺肿瘤、匹配的正常相邻实质组织和患者来源的异种移植中的表达情况。我们发现,miR-200a、miR-429和miR-205在胰腺肿瘤中经常过度表达,而CDH1下调,ZEB1和ZEB2水平保持不变。此外,我们分别测量了miR-200家族成员与CDH1表达之间的正相关,以及ZEB1与miR-200c、miR-141和miR-205表达之间的负相关。有趣的是,我们在患者来源的异种移植中发现上皮-间质转化调节因子和miR-200成员的表达有显著变化。最后,功能研究表明,miR-141和miR-429抑制胰腺癌细胞的致瘤潜能。综上所述,这项全面分析有力地表明,miR-200家族的微小RNA,尤其是miR-429,可能在胰腺癌中作为肿瘤抑制基因发挥作用。